Xiaomeng Li; Lin Wang; Li Liu; Zihui Zhao; Ye Li; Jiawei Huang; Huiqin Yan; Yiping Jin; Meiyan Sun; Jun Chen; Yingying Ding; Renfang Zhang; Yinzhong Shen; Xiaomeng Li; Lin Wang; Li Liu; Zihui Zhao; Ye Li; Jiawei Huang; Huiqin Yan; Yiping Jin; Meiyan Sun; Jun Chen; Yingying Ding; Renfang Zhang; Yinzhong Shen

doi:10.46234/ccdcw2025.043

[1]

Acquired Immunodeficiency Syndrome Professional Group, Society of Infectious Diseases, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of human immunodeficiency virus infection/acquired immunodeficiency syndrome (2024 edition). Chin J Infect Dis 2024;42(5):257-84. https://rs.yiigle.com/cmaid/1501644. (In Chinese).

[2]

Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. Circulation 2019;140(11):e563 − 95. https://doi.org/10.1161/CIR.0000000000000677.

[3]

D’Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care. Circulation 2008;117(6):743 − 53. https://doi.org/10.1161/CIRCULATIONAHA.107.699579.

[4]

Ambrosioni J, Levi L, Alagaratnam J, Van Bremen K, Mastrangelo A, Waalewijn H, et al. Major revision version 12.0 of the European AIDS clinical society guidelines 2023. HIV Med 2023;24(11):1126-36. http://dx.doi.org/10.1111/hiv.13542.

[5]

Yang XL, Li JX, Hu DS, Chen JC, Li Y, Huang JF, et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese population: the China-PAR project (prediction for ASCVD risk in China). Circulation 2016;134(19):1430 − 40. https://doi.org/10.1161/CIRCULATIONAHA.116.022367.

[6]

Friis-Møller N, Ryom L, Smith C, Weber R, Reiss P, Dabis F, et al. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: the data-collection on adverse effects of anti-HIV drugs (D: A: D) study. Eur J Prev Cardiol 2016;23(2):214 − 23. https://doi.org/10.1177/2047487315579291.

[7]

Li JJ, Zhao SP, Zhao D, Lu GP, Peng DQ, Liu J, et al. 2023 Chinese guideline for lipid management. Front Pharmacol 2023;14:1190934. https://doi.org/10.3389/fphar.2023.1190934.

[8]

Castro V. Compute risk scores for cardiovascular diseases. Version 1.1.1. 2023. https://cran.r-project.org/web/packages/CVrisk. [2024-6-12].

[9]

Savès M, Chêne G, Ducimetière P, Leport C, Le Moal G, Amouyel P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003;37(2):292 − 8. https://doi.org/10.1086/375844.

[10]

Garg N, Muduli SK, Kapoor A, Tewari S, Kumar S, Khanna R, et al. Comparison of different cardiovascular risk score calculators for cardiovascular risk prediction and guideline recommended statin uses. Indian Heart J 2017;69(4):458 − 63. https://doi.org/10.1016/j.ihj.2017.01.015.